Primary Left Atrial Cardiopathy in Transthyretin Amyloidosis Cardiomyopathy by Multimodality Imaging

作者：Benay Özbay, Corey Rearick, Bharadwaj Satyavolu, Prem Soman, Timothy C. Wong, Matthew R. Starr, Bharat Pillai, Jianhui Zhu, Abdullah Zoheb Azhar, William E. Katz, Leyla Elif Sade · 发表于：JACC. Cardiovascular imaging · 年份：2025 · DOI：10.1016/j.jcmg.2025.04.007 · 被引用次数：8 · 研究领域：Amyloidosis: Diagnosis, Treatment, Outcomes、Pericarditis and Cardiac Tamponade、Cardiac tumors and thrombi

BACKGROUND: Thrombotic event (TE) risk is high in transthyretin amyloid cardiomyopathy (ATTR-CM). OBJECTIVES: The authors sought to explore left atrial (LA) remodeling in ATTR-CM and its association with TE risk in comparison to other phenotypes of left ventricular hypertrophy (LVH). METHODS: Subjects who underwent speckle tracking echocardiography, Tc-99m pyrophosphate scintigraphy, serum and urine immune electrophoresis, per registry protocol, were retrospectively identified (n = 405). Cardiac magnetic resonance and endomyocardial biopsy were used per clinical indication. Subjects with cardiac amyloidosis other than ATTR-CM were excluded, those with nonamyloid LVH served as controls. Propensity score matching was performed for age, sex, coronary artery disease, and diabetes. Longitudinal follow-up was performed over 5 years for TEs. RESULTS: -VASc or prevalent AF at baseline, in ATTR-CM. CONCLUSIONS: -VASc, and LA dilatation, unlike other LVH phenotypes.